Portal de Periódicos da CAPES

We Need Both Randomized Trials and Real-World Data: The Example of Everolimus as Second-Line Therapy for mRCC

2014; Future Medicine; Volume: 10; Issue: 12 Linguagem: Inglês

10.2217/fon.14.182

1744-8301

Mimma Rizzo, Giacomo Cartenì, Giovanni Pappagallo,

Cancer Genomics and Diagnostics

Future OncologyVol. 10, No. 12 EditorialWe need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCCMimma Rizzo, Giacomo Cartenì & Giovanni PappagalloMimma Rizzo UOC di Oncologia, Azienda Ospedaliera 'A. Cardarelli', Naples, Italy, Giacomo Cartenì UOC di Oncologia, Azienda Ospedaliera 'A. Cardarelli', Naples, Italy & Giovanni Pappagallo*Author for correspondence: E-mail Address: giovanni.pappagallo@gmail.com Ufficio di Epidemiologia & Sperimentazioni Cliniche, Dipartimento di Scienze Mediche, U.O.C. di Oncologia & Ematologia Oncologica; Azienda Sanitaria ULSS 13, via L. Mariutto, 76-30035 Mirano, Venice, ItalyPublished Online:11 Nov 2014https://doi.org/10.2217/fon.14.182AboutSectionsView ArticleView Full TextSupplemental MaterialPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: everolimusmRCCobservational studiesrandomized trialssecond-line therapyReferences1 Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 15(5), 423–434 (1999).Crossref, Medline, CAS, Google Scholar2 Silverman SL. From randomized controlled trials to observational studies. Am. J. Med. 122(2), 114–120 (2009).Crossref, Medline, Google Scholar3 Riegelman R. Studying a Study and Testing a Test: How to Read the Medical Evidence. Lippincott Williams & Wilkins, PA, USA (2000).Google Scholar4 Landewé R, van der Heijde D. Primer: challenges in randomized and observational studies. Nat. Clin. Pract. Rheumatol. 3(11), 661–666 (2007).Crossref, Medline, Google Scholar5 Ray WA. Population-based studies of adverse drug effects. N. Engl. J. Med. 349(17), 1592–1594 (2003).Crossref, Medline, CAS, Google Scholar6 Avorn J. In defense of pharmaco-epidemiolology – embracing the yin and yang of drug research. N. Engl. J. Med. 357(22), 2219–2221 (2007).Crossref, Medline, CAS, Google Scholar7 Lubeck DP. Use of observational databases (registries) in research. In: Clinical Research Methods for Surgeons. Penson DF, Wei JT (Eds). Humana Press, NY, USA, 95–104 (2007).Crossref, Google Scholar8 Hiatt WR. Observational studies of drug safety – aprotinin and the absence of transparency. N. Engl. J. Med. 355(21), 2171–2173 (2006).Crossref, Medline, CAS, Google Scholar9 Avorn J. Dangerous deception – hiding the evidence of adverse drug events. N. Engl. J Med. 355(21), 2169–2171 (2006).Crossref, Medline, CAS, Google Scholar10 Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(8), 4256–4265 (2010).Crossref, Medline, CAS, Google Scholar11 Zustovich F, Lombardi G, Nicoletto O, Pastorelli D. Second-line therapy for refractory renal-cell carcinoma. Crit. Rev. Oncol. Hematol. 83(1), 112–122 (2012).Crossref, Medline, Google Scholar12 Grünwald V, Karakiewicz PI, Bavbek SE et al. REACT Study Group. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur. J. Cancer 48(3), 324–332 (2012).Crossref, Medline, CAS, Google Scholar13 Albiges L, Bergmann L, Eymard JC et al. Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: Preliminary results of a pooled analysis of non interventional studies. J. Clin. Oncol. 31(6), Abstract 392 (2013).Google Scholar14 Rizzo M, Facchini G, Savastano C et al. Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study. Future Oncol. doi:10.2217/FON.14.170 (2014) (Epub ahead of print).Google Scholar15 ABPI. abpi.org.uk/our-work/library/guidelines/Documents/2011–06–13Google ScholarFiguresReferencesRelatedDetailsCited ByGenomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma20 October 2023 | Current Oncology, Vol. 30, No. 10Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study21 March 2023 | Targeted Oncology, Vol. 18, No. 2Lenvatinib in differentiated thyroid carcinoma: the Italian experienceAlessandro Piovesan6 August 2019 | Future Oncology, Vol. 15, No. 24sMRI ultrasound fusion biopsy in prostate cancer detection: Are randomized clinical trials reproducible in everyday clinical practice?19 March 2019 | Urologia Journal, Vol. 86, No. 1Dabrafenib–trametinib combination in 'field-practice': an Italian experienceRoberta Depenni, Francesco De Rosa, Stefano Greco, Laura Ridolfi, Giovanni Pellacani, Giovanni Ponti, Stefano Cascinu & Massimo Guidoboni7 August 2018 | Future Oncology, Vol. 14, No. 20Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access programSergio Bracarda, Luca Galli, Marco Maruzzo, Giovanni Lo Re, Sebastiano Buti, Adolfo Favaretto, Francesco Di Costanzo, Cosimo Sacco, Marco Merlano, Claudia Mucciarini, Elena Zafarana, Sante Romito, Antonio Maestri, Carmelo G Giorgio, Maria T Ionta, Daniele Turci, Ugo De Giorgi, Giuseppe Procopio, Enrico Cortesi, Diana Giannarelli & Camillo Porta18 May 2018 | Future Oncology, Vol. 14, No. 14Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patientsErica Quaquarini, Federico Sottotetti, Daniela D'Ambrosio, Alberto Malovini, Stefania Morganti, Arianna Marinello, Lorenzo Pavesi & Mara Frascaroli8 May 2017 | Future Oncology, Vol. 13, No. 11sPomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myelomaConcetta Conticello, Marina Parisi, Alessandra Romano, Valeria Calafiore, Flavia Ancora, Alessia La Fauci, Maria Letizia Consoli & Francesco Di Raimondo24 January 2017 | Future Oncology, Vol. 13, No. 5sPomalidomide in heavily pretreated refractory multiple myeloma: a case reportAngelo Palmas, Giovanna Piras, Antonella Uras, Rosanna Asproni, Marco Murineddu, Maria Monne, Roberta Stradoni & Giancarlo Latte24 January 2017 | Future Oncology, Vol. 13, No. 5sPomalidomide: when expectations are understatedFrancesco Di Raimondo & Concetta Conticello24 January 2017 | Future Oncology, Vol. 13, No. 5sEribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes14 October 2016 | The Oncologist, Vol. 21, No. 11One-year outcomes of a BioMime™ Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in all-comers coronary artery disease patients: The meriT-3 studyIndian Heart Journal, Vol. 68, No. 5More colors to the paletteAnnals of Oncology, Vol. 27, No. 23-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experienceMichele Caruso, Gaetano Castiglione, Rosanna Aiello, Marco Alí, Maurizio Chiarenza, Rosanna Dimarco, Giuseppa Fallica, Maria Grazia Di Leo, Maria Vita Sanó, Eleonora Taibi, Alessandra Zacchia, Eleonora Miano & Francesco Caruso6 November 2015 | Future Oncology, Vol. 11, No. 23Everolimus treatment in advanced solid tumors: a personal viewFuture Science OA, Vol. 1, No. 3Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma30 June 2015 | Therapeutic Advances in Urology, Vol. 7, No. 5Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case reportLuigi Leo, Francesca Caputo, Antonella Di Sarno, Tiziana Garofano, Francesca Andreozzi, Maria Grazia Massaro & Vincenzo Montesarchio3 August 2015 | Future Oncology, Vol. 11, No. 15sEribulin in 'field practice': an overview of the Italian experienceSandro Barni3 August 2015 | Future Oncology, Vol. 11, No. 15sVemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety studyMichele Del Vecchio, Paolo Antonio Ascierto, Mario Mandalà, Vanna Chiarion Sileni, Michele Maio, Lorenza Di Guardo, Ester Simeone & Paola Queirolo8 May 2015 | Future Oncology, Vol. 11, No. 9 Vol. 10, No. 12 STAY CONNECTED Supplemental MaterialsMetrics Downloaded 140 times History Published online 11 November 2014 Published in print October 2014 Information© Future Medicine LtdKeywordseverolimusmRCCobservational studiesrandomized trialssecond-line therapyFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, PhD, on behalf of Content Ed Net; this assistance was funded by Novartis.PDF download